Anad Salem, MD
Family Medicine · Carbondale, ILNPI 1659366839
Payments from drug & device makers
Across 272 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$842
- Lilly USA, LLC$835
- AstraZeneca$413
- Pfizer$324
- AbbVie$306
- Amgen$164
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,41899%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $842 |
| Lilly USA, LLC | 50 | $835 |
| AstraZeneca | 29 | $413 |
| Pfizer | 19 | $324 |
| AbbVie(2 entities) | 16 | $306 |
| Amgen | 10 | $164 |
| Axsome Therapeutics, Inc. | 6 | $156 |
| Johnson & Johnson | 13 | $141 |
| Dexcom, Inc. | 7 | $135 |
| Corcept Therapeutics | 7 | $128 |
| Mylan Specialty L.p. | 7 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $99 |
| Aimmune Therapeutics, Inc. | 4 | $90 |
| Viatris Specialty LLC | 4 | $84 |
| Boehringer Ingelheim | 5 | $77 |
| GSK | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $65 |
| Lundbeck LLC | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Novartis | 3 | $55 |
| Merck | 3 | $50 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Insulet Corporation | 1 | $25 |
| GE HealthCare | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
How this compares
$4,471 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 17 | $186,284 |
| JardianceEmpagliflozin | 70 | $93,352 |
| EliquisApixaban | 74 | $84,322 |
| TrulicityDulaglutide | 33 | $63,747 |
| RybelsusSemaglutide | 33 | $58,808 |
| OzempicSemaglutide | 35 | $52,664 |
| JanuviaSitagliptin Phosphate | 34 | $49,787 |
| FarxigaDapagliflozin Propanediol | 45 | $38,927 |
| MounjaroTirzepatide | 28 | $34,033 |
| XareltoRivaroxaban | 34 | $29,377 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $28,435 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $18,635 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $16,626 |
| WegovySemaglutide | 12 | $15,686 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $15,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic, Wegovy | $842 | $127,15880 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $835 | $97,78061 claims |
| Boehringer IngelheimJardiance | $77 | $93,35270 claims |
| PfizerEliquis | $324 | $84,32274 claims |
| MerckJanuvia, Janumet | $50 | $68,42249 claims |
| AstraZenecaFarxiga | $413 | $38,92745 claims |
| Johnson & JohnsonXarelto | $141 | $29,37734 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $70 | $29,09831 claims |
| AbbVieLinzess, Synthroid | $306 | $12,60356 claims |
| NovartisEntresto | $55 | $10,04012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Carbondale
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.